Amgen third-quarter revenue falls 3%, biosimilar sales rise


By Deena Beasley

Oct 29 (Reuters) - Amgen Inc AMGN.O on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the company raised its full-year outlook.

The California based biotechnology company posted adjusted earnings per share of $3.66, beating the average analyst estimate by 13 cents, according to IBES data from Refinitiv. Share buybacks lowered the number of Amgen shares outstanding by 7% from a year earlier.

Amgen, which has its own biosimilar versions of several drugs sold by rival companies, said sales of those products rose to $173 million from $82 million in the previous quarter.

"The quarter was marked by continued questions around some of their key franchises," Jefferies analyst Michael Yee told Reuters. "There were some offsetting surprises. The biosimilar business ... is on a run rate for nearly a billion (dollars) by next year."

Amgen shares, which closed up 2% at $208.99 - near their all-time high - were trading close to that after hours.

Sales of new migraine drug Aimovig totaled $66 million for the quarter, well short of the $94.5 million projected by analysts, while sales of cholesterol fighter Repatha rose 40% to $168 million. That was still shy of Wall Street estimates of $170.3 million.

Sales of Neulasta, which fights infections by boosting white blood cells, fell 32% to $711 million and sales of kidney drug Sensipar plunged 73% to $109 million in the face of increased competition from cheaper generics and biosimilars.

The company said it now expects full-year adjusted earnings of $14.20 to $14.45 per share on revenue of $22.8 billion to $23 billion. It had previously forecast $13.75 to $14.30 per share on revenue of $22.4 billion to $22.9 billion.

Analysts' earnings estimates for 2019 were already ahead of the older forecast at $14.39 per share.

Amgen's revenue for the quarter declined to $5.74 billion from $5.9 billion a year ago, which was slightly better than analysts’ estimates of $5.64 billion.

(Reporting By Deena Beasley Editing by Bill Berkrot)

((; 213 955 6746; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.